Cagrilintide Research Protocol: Evidence & Vial Reference

Cagrilintide is a long-acting amylin analogue investigated in monitored weight-management studies. A 5 mg research vial describes the product's nominal content; it is not a studied dose, a treatment instruction or an approved medicine. For research purposes only.

Research classification: Investigational · published phase 2 dose-finding study. The Cagrilintide 5 mg vial label reports nominal content; it does not state a suitable amount for human use.

Long-acting amylin receptor agonist that reduces appetite, slows gastric emptying, and promotes satiety signaling in the brain of test subjects.

Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.

A published phase 2 dose-finding trial assigned different participants to five once-weekly dose groups: 0.3, 0.6, 1.2, 2.4 or 4.5 mg. These are separate studied arms, not five consecutive steps of a regimen. The supervised trial formulation does not establish a diluent, injection instructions or a clinical schedule for Peak Peptides Australia's 5 mg research vial.

For the existing schedule, its evidence caveats and the concentration calculator, see the Cagrilintide protocol and vial reference. Figures displayed there are research context, not a personalised prescription.

An exact-matching Peak Peptides Australia 5 mg vial is shown on the research reference page. The product is supplied for in-vitro research, not administration.

Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.

View Peak Peptides Australia's research-only listing and confirm its current labelled strength.

• Lau et al. (2021), phase 2 cagrilintide dose-finding trial — The Lancet / PubMed
• NCT03856047 trial-arm registry — ClinicalTrials.gov

For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.